A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Effect of Vandetanib on Cellular Markers of Proliferation and Apoptosis in Invasive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Vandetanib (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- 10 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 10 Jun 2017 Biomarkers information updated
- 20 Feb 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Jul 2017.